Showing results (171-180 of 1,607) with videos related to

Sort By:
Pageof 161
JAMA Oncology|June 3, 2021
Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate CancerFelix Y Feng, Shibu Thomas, Fred Saad, et al.
JAMA Oncology|June 3, 2021
Assessing the Association of Targeted Therapy and Intracranial Metastatic DiseaseAnders W Erickson, Steven Habbous, Frances Wright, et al.
JAMA Oncology|June 3, 2021
Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers: A Nonrandomized Controlled TrialMiranda P Steenbeek, Marline G Harmsen, Nicoline Hoogerbrugge, et al.
JAMA Oncology|November 19, 2020
Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical TrialEmese Zsiros, Sarah Lynam, Kristopher M Attwood, et al.
JAMA Oncology|November 19, 2020
Reproductive Outcomes After Breast Cancer in Women With vs Without Fertility PreservationAnna Marklund, Frida E Lundberg, Sandra Eloranta, et al.
JAMA Oncology|January 7, 2021
Frequency of and Factors Associated With Nonmedical Opioid Use Behavior Among Patients With Cancer Receiving Opioids for Cancer PainSriram Yennurajalingam, Joseph Arthur, Suresh Reddy, et al.
JAMA Oncology|January 7, 2021
Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical TrialHiroaki Akamatsu, Yukihiro Toi, Hidetoshi Hayashi, et al.
JAMA Oncology|February 21, 2020
Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled TrialSalma K Jabbour, Abigail T Berman, Roy H Decker, et al.
JAMA Oncology|February 14, 2020
Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical TrialFausto Petrelli, Roberto Labianca, Alberto Zaniboni, et al.
JAMA Oncology|March 6, 2020
Evaluating the Use of Circulating MicroRNA Profiles for Lung Cancer Detection in Symptomatic PatientsTobias Fehlmann, Mustafa Kahraman, Nicole Ludwig, et al.
Pageof 161